Wealthfront takes new $20.67M stake in Vertex Pharmaceuticals
What's the deal? Wealthfront Advisers LLC bought a new stake in Vertex Pharmaceuticals worth about $20,668,000, according to its latest 13F filing with the US Securities and Exchange CommissionDealroom has a profile for this one. Try Dealroom →. The investment adviser acquired 41,608 shares of the biotech during the second quarter of 2026.
The company: Vertex Pharmaceuticals carries a market capitalisation of $134.05 billion. Its stock opened at $528.19 on Wednesday, near its 52-week high of $546.17 and above its low of $374.17.
By the numbers: Vertex reported second-quarter 2026 revenue of $3.33 billion, up 12.5% year-on-year and ahead of the $3.23 billion consensus. Earnings came in at $4.73 per share, just below analysts' $4.74 estimate.
Who else is in? Institutional investors and hedge funds own 90.96% of the stock. Recent smaller buyers included Meeder Asset ManagementDealroom has a profile for this one. Try Dealroom →, Swiss ReDealroom has a profile for this one. Try Dealroom →, and Community Financial Services GroupDealroom has a profile for this one. Try Dealroom →.
The signal: Analysts remain broadly positive. Sanford C. BernsteinDealroom has a profile for this one. Try Dealroom → upgraded Vertex to "strong-buy," while the consensus rating stands at "Moderate Buy" with a $563.50 price target — leaving Wealthfront in step with a market that still sees room to run.
Read more: Ticker Report
Image credit: U.S. Department of Energy
